D530049N12Rik Activators
Pramel13os, or PRAME-like 13 on the opposite strand, is a gene with a significant impact on various cellular processes. While its exact function is not explicitly stated, the involvement of Pramel13os in cellular regulation suggests a crucial role in maintaining cellular homeostasis. The activation of Pramel13os can be achieved through both direct and indirect means, with a focus on epigenetic modulation and pathway regulations. Epigenetic modulators, such as histone deacetylase inhibitors (Valproic Acid, Trichostatin A, Sodium Butyrate, Suberoylanilide Hydroxamic Acid), DNA methyltransferase inhibitors (5-Azacytidine), and bromodomain inhibitors (JQ1, BIX-01294, PFI-3), influence Pramel13os expression through chromatin modifications. Additionally, pathway regulators like SB431542 (TGF-β receptor inhibitor), PD0325901 (MEK inhibitor), and LY294002 (PI3K inhibitor) indirectly activate Pramel13os by influencing key signaling pathways.
Understanding the intricate regulatory mechanisms of Pramel13os activation sheds light on its potential role in cellular processes. The interplay between epigenetic modifications and pathway regulations highlights the sophisticated nature of Pramel13os regulation within cellular contexts, emphasizing its significance in maintaining cellular homeostasis and function. Further exploration into the detailed mechanisms of Pramel13os activation will provide valuable insights into its role in cellular physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, a histone deacetylase inhibitor, indirectly activates Pramel13os by modulating epigenetic regulation. By inhibiting HDACs, it promotes histone acetylation, leading to increased Pramel13os expression and function within cellular processes. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, indirectly activates Pramel13os through epigenetic modulation. By inhibiting DNA methylation, it facilitates the transcriptional activation of Pramel13os, resulting in heightened expression and cellular effects mediated by Pramel13os. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, influences Pramel13os activation through epigenetic regulation. By inhibiting HDACs, it promotes histone acetylation, leading to increased Pramel13os expression and subsequent effects within cellular processes. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, an HDAC inhibitor, indirectly activates Pramel13os by modulating epigenetic regulation. Inhibiting HDACs promotes histone acetylation, enhancing Pramel13os expression and contributing to heightened cellular processes where Pramel13os plays a vital role. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly activates Pramel13os by suppressing the TGF-β pathway. Inhibition of TGF-β signaling leads to increased Pramel13os expression and function, illustrating the intricate regulatory networks governing Pramel13os within cellular contexts. | ||||||
BIX01294 hydrochloride | 1392399-03-9 | sc-293525 sc-293525A sc-293525B | 1 mg 5 mg 25 mg | $37.00 $112.00 $408.00 | ||
BIX-01294, a G9a histone methyltransferase inhibitor, indirectly activates Pramel13os through epigenetic modulation. Inhibiting G9a promotes the transcriptional activation of Pramel13os, resulting in heightened expression and subsequent cellular effects mediated by Pramel13os. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a BET bromodomain inhibitor, indirectly activates Pramel13os via epigenetic modulation. By inhibiting bromodomain-containing proteins, JQ1 promotes the transcriptional activation of Pramel13os, leading to increased expression and cellular effects mediated by Pramel13os. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid, an HDAC inhibitor, indirectly activates Pramel13os through epigenetic modulation. By inhibiting HDACs, it promotes histone acetylation, leading to increased Pramel13os expression and subsequent cellular effects mediated by Pramel13os within various cellular contexts. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates Pramel13os by modulating the PI3K/Akt pathway. Inhibition of PI3K leads to enhanced Pramel13os expression and function, providing insight into the intricate regulatory mechanisms governing Pramel13os activity within cellular signaling networks. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485, a histone deacetylase 7 (HDAC7) inhibitor, indirectly activates Pramel13os through epigenetic regulation. By inhibiting HDAC7, it promotes histone acetylation, leading to increased Pramel13os expression and subsequent cellular effects mediated by Pramel13os within various cellular contexts. | ||||||